Medprio Life Sciences Profile
Key Indicators
- Authorised Capital ₹ 0.20 M
as on 14-12-2024
- Paid Up Capital ₹ 0.10 M
as on 14-12-2024
- Company Age 9 Year, 9 Months
- Last Filing with ROC 31 Mar 2024
- Revenue 15.23%
(FY 2022)
- Profit 8.89%
(FY 2022)
- Ebitda 5.48%
(FY 2022)
- Net Worth 40.01%
(FY 2022)
- Total Assets 2.83%
(FY 2022)
About Medprio Life Sciences
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.20 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Nanu Aggarwal, Vikas Aggarwal, and Babita Bansal serve as directors at the Company.
- CIN/LLPIN
U33111DL2015PTC277683
- Company No.
277683
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
09 Mar 2015
- Date of AGM
24 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Delhi, India
- Telephone
- Email Address
- Website
-
- Social Media-
What products or services does Medprio Life Sciences Private Limited offer?
Medprio Life Sciences Private Limited offers a wide range of products and services, including Surgical Needles, Spinal Needle, Disposable Cannulas, IV Cannula, Surgical Disposables, Bone Wax, Surgical & Medical Consumables, Forceps & Graspers, Surgical Staplers, Infusion Syringes & Supplies.
Who are the key members and board of directors at Medprio Life Sciences?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Nanu Aggarwal  | Director | 09-Mar-2015 | Current |
| Vikas Aggarwal | Director | 09-Mar-2015 | Current |
| Babita Bansal | Director | 12-Oct-2017 | Current |
Financial Performance of Medprio Life Sciences.
Medprio Life Sciences Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 15.23% increase. The company also saw a slight improvement in profitability, with a 8.89% increase in profit. The company's net worth Soared by an impressive increase of 40.01%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Medprio Life Sciences?
In 2019, Medprio Life Sciences had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Kskv Research And Technologies Private LimitedActive 1 year 5 monthsBabita Bansal is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Medprio Life Sciences?
Unlock and access historical data on people associated with Medprio Life Sciences, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Medprio Life Sciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Medprio Life Sciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
